Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alopecia, Androgenetic: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Alopecia, Androgenetic: 4 US clinical trials tracked, none currently recruiting.
Alopecia, Androgenetic is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Technoderma Medicines, running 2 of these trials.
Enrollment posture brief
Registry condition alopecia-androgenetic
OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Alopecia, Androgenetic has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alopecia, Androgenetic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alopecia, Androgenetic is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
Cassiopea SpA
NCT05910450
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Allergan
NCT01904721
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Technoderma Medicines
NCT05802173
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Technoderma Medicines
NCT05244980
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alopecia, Androgenetic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alopecia, Androgenetic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alopecia, Androgenetic page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Alopecia, Androgenetic trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Technoderma Medicines sponsors the most Alopecia, Androgenetic trials on record, review their full trial history before evaluating a specific study. See Technoderma Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alopecia, Androgenetic condition card totals 4 registered trials; most-linked intervention TDM-105795 topical vehicle solution; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.